Q-Vant Biosciences collaborates with Tulane University to develop a promising new oral vaccine adjuvant
Q-Vant Biosciences Inc., a biosciences company specialized in manufacturing and formulating open-access saponin-based adjuvants from...
Read more
Latest News -Uncategorized
Q-VANT and SPI Pharma offering broader access to sustainable and scalable pharma-grade saponin adjuvants
SPI Pharma, Inc. and Q-Vant Biosciences, Inc. announce a strategic partnership which includes an investment to expand Q-Vant’s...
Read more
Q-Vant Biosciences Announces Positive Study Results for Its Sustainable Quillaja-Based Vaccine Adjuvant, Q-VET-S®, in Kansas State’s Classic Swine Fever Vaccine
BOSTON, MA May 23, 2023 – Q-Vant Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market...
Read more
Q-VANT Biosciences enters Vaccine Research Master Agreement with Kansas State University Teams to study the impact of saponin-based adjuvants on animal vaccine efficacy
BOSTON, MA – April 12, 2022 – Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market...
Read more
Q-VANT and In vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass
Enhances Q-VANT’s 100% sustainable supply for next-generation saponin adjuvants Boston, MA – March 8, 2022 – Q-VANT Biosciences, the first...
Read more
Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines
Company’s Innovative Technology Increases Yield of High-Quality Saponin-Based Adjuvants, Enabling the Sustainable Supply of Billions of Doses...
Read more
Recent Comments